We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
8.00 | 0.49% | 1,647.50 | 1,647.50 | 1,648.50 | 1,656.00 | 1,644.50 | 1,650.50 | 521,098 | 10:10:33 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.79 | 67.97B |
Date | Subject | Author | Discuss |
---|---|---|---|
26/1/2023 15:41 | Its almost a daily event, as soon as Wall Street opens .... ;0) | tradermichael | |
26/1/2023 15:32 | A 10p price change on 1400-odd-p is hardly dramatic especially as the price is effectively level on the day so doesn't justify starting yet another rumour. | grahamburn | |
26/1/2023 15:23 | Is there any breaking rumour that has caused this to go into the RED? Its been GREEN all morning. Any views as to why the change? | netcurtains | |
26/1/2023 14:24 | Thank you BD. I know NC probably cannot see this post (he may well bot have filtered me), but I, like you, I fail to see how quoting/summarising facts from a report can be classified as "agressive". BBs are for reasoned debate and for exchanging opinions and ideas in a civilised, friendly manner. NC saying the report is "sanitised" without providing evidence is verging on a rumour. That is potentially misleading. | grahamburn | |
26/1/2023 09:30 | Haleon releases its fourth quarter and final year 2022 results on 2nd March. Credit Suisse predict organic sales growth of 3.7% and OTC growth of 5.0%. On an earnings discount to European rivals, 'outperform' is the investment rating with a share price target of 376p. | tradermichael | |
26/1/2023 09:28 | Share price recovering a little | alibizzle | |
26/1/2023 08:02 | bothdavis: I did not block him for that. I dont want to discuss it further. Thank you. Its not called debate its called being overly aggressive and self righteous. He had to go. Share investing can get overly emotional and I dont need this agro thrown on top. I personally did not have 4th jab. I'm reasonably glad I did not. Many other people see it differently. I know that. Thank you for not debating this. Ad nauseum | netcurtains | |
25/1/2023 22:25 | Why block grahamburn for stating what is in the report? The review of more than 8,000 reported cases from 46 studies by researchers in Canada confirms previous reports that myocarditis is rare, but cases are highest among young males shortly after a second dose, and are probably higher after Moderna’s mRNA vaccine than after Pfizer’s vaccine. It also shows that, while cases are predominantly mild, the risk of myocarditis or pericarditis might be lower when the second dose is given more than 30 days after the first dose. However, the researchers warn that, in general, the evidence is of low certainty and say these findings must be considered alongside the overall benefits of vaccination. So~: 'confirms previous reports that myocarditis is rare', the evidence is of low certainty and.......findings must be considered alongside the overall benefits of vaccination' It is called 'debate', and I'm afraid it merely backs up the facts that vaccination is the best thing to have done for the population as a whole. | bothdavis | |
25/1/2023 18:49 | grahamburn blocked. (Filtered) | netcurtains | |
25/1/2023 18:25 | Try reading the first line of that report before scaremongering, as well as the second and third lines. To assist, here they are: Number of cases low and predominantly mild Young males at highest risk shortly after second dose, suggesting longer dosing intervals might be beneficial Findings must be considered alongside overall benefits of vaccination Then read and absorb the detail following. Finally, perhaps re-post (or publicly edit) 31452 without "more and more". Facts are always better than rumours. | grahamburn | |
25/1/2023 15:14 | bothdavis: Its not rumour: This is the sanitised version - as news comes out it probably will get worse. I did not have 4th jab. Reasonably happy that I did not (I have had covid - mild case) | netcurtains | |
25/1/2023 14:57 | Haven't heard anything myself with regards to COVID injections, had my four. Whats the rumours? | bothdavis | |
25/1/2023 13:19 | I hear more and more people complaining about phizer Covid-19 injections- great Gsk not involved | netcurtains | |
25/1/2023 12:58 | Here's hoping for a favourable court outcome , and that the trial won't last long and a result issued quickly . Also for haleon to be taken over. | alibizzle | |
25/1/2023 11:17 | This is holding the share price back: Among the state court cases naming GSK, a trial in California is currently scheduled to begin 13 February 2023 and a trial is currently scheduled to begin in Madison County, Illinois in February 2023. Given the early stage of this litigation, it is not possible to quantify or reliably estimate what liability (if any) GSK or any other parties may have in this litigation. A favourable result will see the share price absolutely rocket .... ;o) | tradermichael | |
25/1/2023 09:46 | Is it rising towards next WEDNESDAYS final results? I guess I'll have to wait and see. | netcurtains | |
24/1/2023 21:54 | I'm not GSK's biggest advocate but I very much doubt we'll see £11! | rikky72 | |
24/1/2023 20:06 | This will not impress next week. The books are being printed, the leaks have happened.This has £11 written all over it.It will come good, but not til Q4 | rongetsrich | |
24/1/2023 19:39 | Thanks for the correction Supermarky! Well spotted. | netcurtains | |
24/1/2023 18:12 | We will announce our full year and fourth quarter 2022 results on Wednesday 1 February 2023. | supermarky | |
24/1/2023 17:14 | I'm looking from the sidelines. ADVFN have the dividend at 5.77% at this price, but the chart doesn't look too good. 1350 good entry point if it gets that low? | gswredland | |
24/1/2023 16:59 | Net I'm still out of GSK (waiting for a good point to re-enter). Just wanted to say how much I enjoy reading your informative posts. | jonjoneil | |
24/1/2023 16:05 | TraderMichael: Is it possible that the City knows that TUESDAYS results will be good and this is the crouching down before the rise? | netcurtains | |
24/1/2023 15:43 | 5 years now at the helm for Dame Emma Walmsley. The job is to creat value for shareholders. It is not working the evidence is the share price, the dividend cut and the loss of confidence by the market. How does a failing CEO get removed? Note: by comparison to AZ Pascal Spirit had turned AZ around well before 5 years. | fidepax1 | |
24/1/2023 15:01 | 5 years now at the helm for Dame Emma Walmsley. The job is to creat value for shareholders. It is not working the evidence is the share price, the dividend cut and the loss of confidence by the market. How does a failing CEO get removed? Note: by comparison to AZ Pascal Spirit had turned AZ around well before 5 years. | fidepax1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions